secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2023-01-10T23:59:59+00:00
Accession:  0001193125-23-005019
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO promotes Curran Simpson to COO, Shiva Fritsch to Chief Communications Officer
--------------------------------------------------------------------------------

- Curran Simpson appointed COO effective Jan 9, 2023; previously SVP, Chief Technology and Operations Officer since 2015.
- Shiva Fritsch elevated to Chief Communications Officer while retaining Chief People Officer role; joined REGENXBIO in 2017.
- Promotions follow opening of Manufacturing Innovation Center and progress toward '5 x '25' strategy for five AAV therapeutics.
- Simpson will oversee manufacturing, quality, regulatory, preclinical development, and corporate strategy.
- Fritsch will oversee internal/external communications and human resources.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000119312523005019/0001193125-23-005019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000119312523005019/d120677d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-005019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer